Literature DB >> 27324143

Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism.

Erin R Weeda1, W Frank Peacock2, Gregory J Fermann3, Philip S Wells4, Veronica Ashton5, Concetta Crivera5, Thomas J Bunz6, Peter Wildgoose5, Jeff R Schein5, Craig I Coleman7.   

Abstract

Changes in reimbursement policies have led to an increased use of observation stays in the United States (US). We sought to compare outcomes among pulmonary embolism (PE) patients managed through observation stays or inpatient admissions.The Premier Perspective Comparative Hospital Database was used to identify patients with a primary International Classification of Diseases, ninth-edition diagnosis of PE (415.1×) from 11/2012-3/2015. Patients were required to have claims for ≥1 diagnostic tests for PE on days 0-2 and evidence of PE treatment. Patients managed through observation stays were 1:1 propensity score matched to those undergoing inpatient admissions. We compared length-of-stay (LOS), hospital costs (2015US$) and rates of hospital-acquired conditions and readmission between the cohorts. A total of 1105 PE observation stays were matched to 1105 inpatient admissions. The baseline characteristics of the cohorts were well-balanced (no standardized differences >10 %). Mean ± standard deviation LOS and hospital costs were 3.6 ± 2.6 days and $5423 ± $5770, respectively. LOS was shorter for observation stays 2.3 ± 1.3 days) vs. inpatient admissions (4.9 ± 3.0 days, p < 0.001). This corresponded to a mean $4390 lower treatment costs for observation stays (p < 0.001). Hospital-acquired conditions were less common among observation stay patients vs. inpatients (p < 0.001); driven predominantly by reductions in bacterial pneumonia and Clostridium difficile infection. Readmission for venous thromboembolism or major bleeding in the same or subsequent 2-months did not differ between the cohorts (p ≥ 0.16 for both).Compared with inpatient admissions, observation stays were associated with reduced LOS, costs and hospital-acquired conditions, without increased risk of readmission.

Entities:  

Keywords:  Hospital-acquired; Patient readmission; Propensity score; Venous thromboembolism

Mesh:

Year:  2016        PMID: 27324143     DOI: 10.1007/s11239-016-1391-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  14 in total

1.  Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.

Authors:  Alex C Spyropoulos; Jay Lin
Journal:  J Manag Care Pharm       Date:  2007 Jul-Aug

Review 2.  Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system.

Authors:  Eyal Zimlichman; Daniel Henderson; Orly Tamir; Calvin Franz; Peter Song; Cyrus K Yamin; Carol Keohane; Charles R Denham; David W Bates
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

Review 3.  Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.

Authors:  Craig A Umscheid; Matthew D Mitchell; Jalpa A Doshi; Rajender Agarwal; Kendal Williams; Patrick J Brennan
Journal:  Infect Control Hosp Epidemiol       Date:  2011-02       Impact factor: 3.254

4.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

5.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

Review 6.  Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis.

Authors:  Christine G Kohn; Elizabeth S Mearns; Matthew W Parker; Adrian V Hernandez; Craig I Coleman
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

7.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

8.  Time trends in pulmonary embolism in the United States: evidence of overdiagnosis.

Authors:  Renda Soylemez Wiener; Lisa M Schwartz; Steven Woloshin
Journal:  Arch Intern Med       Date:  2011-05-09

Review 9.  Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis.

Authors:  Siavash Piran; Grégoire Le Gal; Philip S Wells; Esteban Gandara; Marc Righini; Marc A Rodger; Marc Carrier
Journal:  Thromb Res       Date:  2013-08-28       Impact factor: 3.944

10.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

View more
  2 in total

1.  Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism.

Authors:  R Ghazvinian; A Gottsäter; J L Elf
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

Review 2.  Reducing the hospital burden associated with the treatment of pulmonary embolism.

Authors:  W Frank Peacock; Adam J Singer
Journal:  J Thromb Haemost       Date:  2019-04-01       Impact factor: 5.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.